pediatric fever 29 to 60 daysMANAGEMENT

PEDIATRIC-SPECIFIC PRESENTATIONS · 12 SECTIONS

⚲

529 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Pediatric-Specific Presentations13▾

Bronchiolitis Croup Emergency delivery Febrile seizure Intussusception Kawasaki disease Neonatal jaundice Neonatal sepsis Nursemaid's elbow Pediatric fever 0 to 28 days Pediatric fever 29 to 60 days Pediatric fever 61 to 90 days Pyloric stenosis

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp86

Triage and stabilization

›Immediate priorities

›Fever definition

›Rectal temperature 38.0 C or higher

›Immediate risk flags

›Toxic appearance

›Lethargy

›Inconsolability

›Poor perfusion

›Cyanosis

›Apnea

›Seizure

›Persistent vomiting

›Respiratory distress

›Resuscitation triggers

›Shock physiology

›Tachycardia out of proportion

›Hypotension

›Capillary refill 3 seconds or longer

›Cool extremities

›Altered mental status

›Escalate to resuscitation bay for any shock physiology

›Airway and breathing targets

›Oxygen saturation 94 percent or higher

›Work of breathing normalization

›Circulation targets

›Normotension for age

›Capillary refill under 2 seconds

›Urine output 1 mL per kg per hour or higher

›Monitoring

›Continuous pulse oximetry

›Cardiac monitoring

›Frequent reassessment of perfusion and mental status

›Vascular access

›Peripheral IV

›IO if IV access delayed and unstable

Initial risk stratification 29 to 60 days

›Risk groups

›Population definition

›Age 29 to 60 days

›Previously healthy

›Born at 37 weeks gestation or later

›No chronic medical condition

›No indwelling hardware

›No immunodeficiency

›No recent hospitalization

›Exclusion features

›Prematurity under 37 weeks gestation

›Complex congenital heart disease

›Chronic lung disease with oxygen requirement

›Immunocompromise

›Central line or VP shunt

›Recent antibiotics within 48 hours

›Clinical appearance branch

›Ill appearing pathway

›Full sepsis evaluation

›Empiric parenteral antibiotics

›Hospital admission

›Well appearing pathway

›Urinalysis plus inflammatory markers plus blood culture

›Lumbar puncture based on inflammatory markers and shared decision-making

Key clinical decision points

›Decision nodes

›Inflammatory markers definition

›Procalcitonin

›C reactive protein

›Absolute neutrophil count

›Abnormal inflammatory markers

›Temperature over 38.5 C

›Procalcitonin over 0.5 ng per mL

›C reactive protein over 20 mg per L

›Absolute neutrophil count over 4000 to 5200 per microL

›Urinalysis interpretation

›Positive leukocyte esterase

›Positive nitrite

›Pyuria over 5 WBC per hpf

›Low risk well appearing definition

›Urinalysis negative

›Inflammatory markers normal

›No focal bacterial source

›High risk well appearing definition

›Any abnormal inflammatory marker

›Urinalysis suggestive of UTI

›Clinician concern despite normal markers

›Lumbar puncture decision

›Perform LP if ill appearing

›Perform LP if abnormal inflammatory markers and no alternative source

›Consider LP if urinalysis positive and inflammatory markers abnormal

›Shared decision-making for LP if borderline markers and reliable follow-up

02History/hx55

Eligibility and exclusions

›Population screen

›Age confirmation

›Chronologic age 29 to 60 days

›Birth history

›Gestational age at birth

›NICU stay

›Perinatal infections

›Past medical history exclusions

›Prematurity under 37 weeks

›Congenital anomalies affecting immunity

›Prior invasive bacterial infection

›Recent care

›Recent antibiotics within 48 hours

›Recent immunizations within 48 hours

›Recent hospitalization or ED visit

High risk historical features

›Risk features

›Fever course

›Duration of fever

›Highest recorded temperature

›Feeding and hydration

›Poor feeding

›Decreased wet diapers

›Neurobehavioral change

›Decreased responsiveness

›Persistent irritability

›Respiratory symptoms

›Apnea

›Increased work of breathing

›GI symptoms

›Persistent vomiting

›Bloody stool

›Skin and soft tissue

›Rash

›Vesicles

›Omphalitis concern

›HSV risk signals

›Vesicular lesions

›Seizure

›Maternal HSV near delivery

›Elevated transaminases history

›Hypothermia history

Exposures and context

›Infectious context

›Sick contacts

›Household viral illness

›Daycare exposure

›Maternal history

›GBS status

›Chorioamnionitis

›Intrapartum antibiotics

›Travel and outbreaks

›Recent travel

›Local respiratory virus surge

›Medications

›Antipyretic use

›Prior antibiotics

03Physical Exam/exam50

Appearance and perfusion

›General assessment

›Pediatric assessment triangle domains

›Appearance

›Work of breathing

›Circulation to skin

›Perfusion

›Capillary refill time

›Peripheral temperature

›Mottling

›Mental status

›Arousability

›Consolability

›Hydration

›Fontanelle

›Mucous membranes

›Tears

›Skin turgor

Source evaluation

›Focused exam for source

›HEENT

›Otitis media findings

›Conjunctivitis

›Neck

›Meningismus

›Bulging fontanelle

›Chest

›Increased work of breathing

›Focal crackles

›Cardiac

›Murmur

›Tachycardia persistence

›Abdomen

›Tenderness

›Distension

›GU

›Circumcision status

›Suprapubic tenderness

›Skin

›Cellulitis

›Abscess

›Petechiae

›Purpura

›Vesicles

›MSK

›Pseudoparalysis

›Joint swelling

PITFALLS

›Common pitfalls

›Normal appearance early in sepsis

›Rapid deterioration risk in young infants

›Viral symptoms with concurrent UTI

›UTI risk persists with bronchiolitis and RSV

04Differential Diagnosis/ddx51

Serious bacterial infection and IBI

›High consequence diagnoses

›Urinary tract infection

›ICD-10 N39.0

›SNOMED CT urinary tract infectious disease

›Bacteremia

›ICD-10 R78.81

›SNOMED CT bacteremia

›Bacterial meningitis

›ICD-10 G00.9

›SNOMED CT bacterial meningitis

›Pneumonia

›ICD-10 J18.9

›SNOMED CT pneumonia

›Cellulitis

›ICD-10 L03.90

›SNOMED CT cellulitis

›Osteomyelitis

›ICD-10 M86.9

›SNOMED CT osteomyelitis

›Septic arthritis

›ICD-10 M00.9

›SNOMED CT septic arthritis

›Sepsis

›ICD-10 A41.9

›SNOMED CT sepsis

Viral and nonbacterial infections

›Common alternatives

›Viral upper respiratory infection

›ICD-10 J06.9

›Bronchiolitis

›ICD-10 J21.9

›Influenza

›ICD-10 J10.1

›SARS CoV 2 infection

›ICD-10 U07.1

›RSV infection

›ICD-10 B97.4

›Enterovirus infection

›ICD-10 B34.1

›HSV infection

›ICD-10 B00.9

Noninfectious mimics

›Mimics

›Dehydration

›ICD-10 E86.0

›Overbundling

›Environmental hyperthermia

›Congenital heart disease decompensation

›Poor perfusion without infection

›Metabolic disorder

›Lethargy and poor feeding

›Vaccine reaction

›Fever after immunization within 48 hours

05Laboratory Tests/lt52

Core studies

›Baseline labs for well appearing 29 to 60 days

›Blood culture

›Obtain prior to antibiotics when feasible

›Contaminant interpretation based on organism and clinical course

›Complete blood count with differential

›Absolute neutrophil count for risk stratification

›WBC count alone insufficient for IBI exclusion

›Urinalysis

›Prefer catheterized specimen

›Bag specimen limited to screening only

›Urine culture

›Obtain with catheterized or SPA specimen

Inflammatory markers

›Inflammatory marker panel

›Procalcitonin

›Low risk threshold 0.5 ng per mL or lower

›PECARN low risk threshold under 1.71 ng per mL

›C reactive protein

›Low risk threshold 20 mg per L or lower

›Absolute neutrophil count

›AAP abnormal threshold over 4000 to 5200 per microL

›Step by Step abnormal threshold over 10000 per microL

›PECARN low risk threshold 4090 per microL or lower

›Temperature effect

›Higher temperature increases IBI probability

CSF studies

›CSF evaluation when LP performed

›CSF cell count with differential

›Pleocytosis interpretation per local age based reference ranges

›CSF Gram stain and culture

›Antibiotics prior to LP reduces culture yield

›CSF glucose

›Low CSF glucose under 2.2 mmol per L

›CSF to serum glucose ratio under 0.4

›CSF protein

›Elevated protein supportive of bacterial meningitis in context

›CSF viral PCR

›Enterovirus PCR if available

›HSV PCR if HSV concern

Additional labs for ill appearing or targeted concerns

›Expanded evaluation triggers

›Blood gas and lactate

›Lactate trend for shock physiology

›Gas reporting in mmHg for oxygen and carbon dioxide tensions

›Serum electrolytes and glucose

›Glucose reporting in mmol per L

›Hepatic panel

›ALT elevation supporting HSV concern

›Coagulation studies

›DIC concern

›Respiratory viral testing

›Influenza

›RSV

›SARS CoV 2

›Positive viral test does not eliminate UTI risk

06Diagnostic Tests/dt55

Scoring Systems

›Risk stratification tools

›AAP 2021 29 to 60 day pathway

›IM abnormal definition

›Temperature over 38.5 C

›Procalcitonin over 0.5 ng per mL

›C reactive protein over 20 mg per L

›Absolute neutrophil count over 4000 to 5200 per microL

›Low risk definition

›Normal IM

›Urinalysis negative

›Well appearing

›PECARN 2019 rule

›Low risk criteria

›Urinalysis negative

›Absolute neutrophil count 4090 per microL or lower

›Procalcitonin under 1.71 ng per mL

›Intended outcome

›Low risk for IBI and serious bacterial infection

›Step by Step approach

›Low risk criteria

›Well appearing

›Age over 21 days

›Urinalysis negative for leukocytes

›Procalcitonin under 0.5 ng per mL

›C reactive protein 20 mg per L or lower

›Absolute neutrophil count 10000 per microL or lower

›Application note

›LP not required for rule application

›Rochester criteria

›Low risk concept

›Well appearing

›No focal infection on exam

›Normal WBC and band count range per local standard

›Urinalysis without pyuria

MRI

›MRI roles

›Limited ED indications

›Suspected osteomyelitis

›Suspected spinal epidural infection

›Constraints

›Need for sedation common in this age group

›Delay incompatible with sepsis instability

›CT roles

›Targeted indications only

›Suspected intracranial complication

›Traumatic concern with fever and lethargy differential

›Constraints

›Radiation risk

›Low yield for isolated fever without localizing signs

Ultrasound

›Ultrasound roles

›POCUS in unstable infant

›Cardiac function and volume assessment

›Pericardial effusion screening

›Renal and bladder ultrasound

›Not routine for first febrile UTI

›Consider after recurrent UTI or atypical course per local guidance

07Disposition/dispo29

Admission and higher level care

›Admission criteria

›Ill appearing infant

›ICU consideration for shock physiology

›Abnormal inflammatory markers with or without LP

›Inpatient observation and cultures pending

›CSF pleocytosis

›Treat as meningitis until proven otherwise

›Parenteral antibiotics required

›Inability to ensure reliable outpatient follow-up

›Social risk

›Caregiver reliability concern

›Transportation barrier

›Follow-up unavailable within 24 hours

Outpatient management

›Discharge home criteria for selected well appearing infants

›Low risk labs

›Urinalysis negative

›Inflammatory markers normal

›Blood culture obtained

›Urine culture obtained

›Clinical stability

›Feeding adequate

›Hydration adequate

›No respiratory distress

›Safety net

›Follow-up arranged within 24 hours

›Caregiver understands return precautions

›Reliable phone access

›Observation option

›ED observation period for reassessment if uncertainty

08Treatment/t66

Empiric antibiotics for possible IBI

›Parenteral antibiotics

›Indications

›Ill appearing

›Abnormal inflammatory markers with concern for IBI

›CSF pleocytosis

›Empiric regimen without meningitis concern

›Ceftriaxone

›50 mg per kg IV or IM every 24 hours

›Maximum 2000 mg per dose

›Avoid if hyperbilirubinemia risk judged significant

›Empiric meningitis regimen

›Cefotaxime

›50 mg per kg IV every 6 to 8 hours

›Meningitis dosing per local protocol

›Vancomycin

›15 mg per kg IV every 6 hours

›Trough based dosing per local protocol

›Renal monitoring

›Sepsis with shock

›Broad coverage per local sepsis pathway

›Third generation cephalosporin plus vancomycin as common pattern

›Add ampicillin if listeria coverage desired by local epidemiology

›Duration decisions

›Stop antibiotics if cultures negative and clinical course reassuring per pathway

UTI directed therapy

›UTI management

›UTI definition support

›Pyuria plus positive culture

›Culture thresholds per specimen type

›Parenteral option

›Ceftriaxone

›50 mg per kg IV or IM every 24 hours

›Step down to oral when improving and tolerating feeds

›Oral options for stable infant when appropriate

›Cephalexin

›25 mg per kg per dose PO every 8 hours

›Maximum per local formulary

›Amoxicillin clavulanate

›Dosing per amoxicillin component

›20 to 30 mg per kg per day divided every 8 hours for susceptible organisms

›Treatment duration

›7 to 10 days typical for febrile UTI

›Narrow based on susceptibilities

HSV directed therapy

›Acyclovir pathway

›Indications in 29 to 60 days

›Vesicular rash

›Seizure

›Severe hepatitis pattern

›CSF pleocytosis with negative Gram stain

›Maternal primary HSV near delivery

›Acyclovir

›20 mg per kg IV every 8 hours

›Renal function monitoring

›Ensure adequate hydration

›Testing bundle when starting acyclovir

›CSF HSV PCR if LP performed

›Surface swabs PCR if available

›Serum ALT

Supportive care

›Symptom management

›Acetaminophen

›15 mg per kg PO every 4 to 6 hours as needed

›Maximum 75 mg per kg per day

›Hydration support

›Oral rehydration support if tolerated

›IV isotonic fluids if poor intake

›Antipyresis note

›Fever response does not reliably distinguish viral from bacterial infection

09Special Populations/sp22

Pregnancy

›Pregnancy considerations

›Not applicable to infant patient

›Confirm caregiver pregnancy only if medication exposure counseling needed

›Household counseling

›Infection prevention and hand hygiene

›Respiratory virus precautions

Geriatric

›Geriatric considerations

›Not applicable to infant patient

›Caregiver support needs may affect discharge safety

›Social supports

›Identify alternate caregiver if primary caregiver limitations

Pediatrics

›Pediatric specific considerations

›Bronchiolitis and viral syndromes

›Lower bacteremia and meningitis risk with clinical bronchiolitis

›UTI risk persists despite bronchiolitis

›Immunization related fever

›Fever within 24 to 48 hours after immunization

›Shared decision-making for extent of workup if otherwise low risk

›Circumcision status

›Higher UTI risk if uncircumcised male

›Weight based dosing

›Dose all antimicrobials by current weight in kg

10Background/b24

Epidemiology

›Disease frequency

›Serious bacterial infection in 29 to 60 day febrile infants

›UTI most common SBI

›Bacteremia uncommon but clinically important

›Bacterial meningitis rare in well appearing with low risk markers

›Viral coinfection

›Viral positivity lowers but does not eliminate IBI risk

Pathophysiology

›Immune vulnerability

›Immature innate and adaptive immunity

›Reduced opsonization and complement activity

›Limited antibody repertoire

›Bacterial translocation risk

›Mucosal barrier immaturity

›Fever physiology

›Cytokine mediated hypothalamic set point shift

Therapeutic Considerations

›Management rationale

›Time sensitive IBI treatment benefit

›Early antibiotics for sepsis and meningitis improves outcomes

›Harm reduction in low risk infants

›Reduce unnecessary LP and hospitalization using validated markers

›Procalcitonin performance

›Earlier rise than CRP in bacterial infection

›Shared decision-making

›Balance small meningitis risk against LP harms and false positives

11Patient Discharge Instructions/pdi24

copy discharge instructions

›Home care and follow-up

›Follow-up plan

›Recheck with primary care or ED within 24 hours

›Culture results follow-up process confirmed

›Fever care

›Acetaminophen dosing per weight

›Avoid ibuprofen under 6 months unless directed

›Hydration

›Frequent feeds

›Monitor wet diapers

›Return to ED now if any red flags

›Worsening lethargy

›Inconsolable irritability

›Poor feeding

›Fewer wet diapers

›Breathing difficulty

›Color change

›Seizure

›New rash with purple spots

›Persistent vomiting

›Appears sicker to caregiver

›Infection control

›Hand hygiene

›Limit sick contacts

12References/r15

Guidelines and evidence sources

›Key sources

›AAP Clinical Practice Guideline 2021 Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days

›Abnormal inflammatory markers include temperature over 38.5 C

›Abnormal inflammatory markers include procalcitonin over 0.5 ng per mL

›Abnormal inflammatory markers include C reactive protein over 20 mg per L

›Abnormal inflammatory markers include absolute neutrophil count over 4000 to 5200 per microL

›Canadian Paediatric Society position statement Management of well-appearing febrile young infants aged 90 days or younger

›Risk stratification incorporating procalcitonin recommended

›Kuppermann et al JAMA Pediatrics 2019 PECARN prediction rule for low risk febrile infants 60 days and younger

›Low risk uses urinalysis plus ANC plus procalcitonin

›Gomez et al 2016 Step by Step approach to febrile infants up to 90 days

›Low risk uses appearance plus age plus urinalysis plus procalcitonin plus CRP plus ANC

›TREKK Fever in Infants 60 days or younger Bottom Line Recommendations v3.0 2025

›Bronchiolitis lowers bacteremia and meningitis risk

›UTI risk persists with bronchiolitis

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.